PT - JOURNAL ARTICLE AU - Lim, Alexandria H AU - Varghese, Chris AU - Sebaratnam, Gabrielle AU - Schamberg, Gabriel AU - Calder, Stefan AU - Gharibans, Armen AU - Andrews, Christopher N AU - Daker, Charlotte AU - Foong, Daphne AU - Ho, Vincent AU - Wise, Michelle R AU - O’Grady, Greg TI - Nausea and Gastric Myoelectrical Activity are Influenced by Hormonal Contraception in Chronic Gastroduodenal Disorders AID - 10.1101/2024.04.20.24306132 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.20.24306132 4099 - http://medrxiv.org/content/early/2024/04/22/2024.04.20.24306132.short 4100 - http://medrxiv.org/content/early/2024/04/22/2024.04.20.24306132.full AB - Background Chronic gastroduodenal disorders such as chronic nausea and vomiting syndrome (CNVS), functional dyspepsia (FD) and gastroparesis, are more prevalent among young women, many of whom are hormonal contraception users. We aimed to evaluate the effects of hormonal contraception on symptom severity and gastric myoelectrical activity in people with chronic gastroduodenal disorders.Methods This analysis was conducted on a large international cohort of patients who met Rome IV criteria for CNVS or FD and had undergone body surface gastric mapping using Gastric Alimetry (Alimetry, New Zealand). Symptoms were continuously reported on 0-10 Likert scales using a validated symptom logging app.Results 127 people were included: 43 females using hormonal contraception, 30 premenopausal females not using hormonal contraception, 30 postmenopausal females, and 24 males. Premenopausal females who used hormonal contraception had higher nausea scores than non-users (3.80 [IQR 2.00-5.42] vs 2.25 [0.20-4.43]; p<0.05), particularly when using the combined oral contraceptive pill (COCP) with hormone-free intervals compared to continuous use (5.20 [4.30-6.00] vs. 2.40 [1.70-3.80], p=0.02). Premenopausal women were more symptomatic than postmenopausal women and men (p<0.001). The Principal Gastric Frequency was higher in hormonal contraception users (median 3.1 cpm [IQR 3.00-3.30] vs. 3.00 cpm [2.90-3.10], p<0.001), and highest in users of progestogen-only formulations (p<0.02).Conclusion Women with gastrointestinal disorders on hormonal contraception experience increased nausea in comparison to non-users of hormonal contraception, with substantial variation in nausea severity dependent on contraceptive type. Hormonal contraception users also demonstrated modified gastric electrophysiology. Women with chronic gastroduodenal symptoms should be asked about their use of hormonal contraception and non-hormonal contraceptive alternatives trialled as a means to reduce symptoms.Competing Interest StatementGOG and AG hold grants and intellectual property in the field of GI electrophysiology. GOG, GS, AG, GSc, SC, CD and CA are members of the University of Auckland spin-out company Alimetry. The remaining authors have no relevant conflicts to declare.Funding StatementThis project was supported by the Health Research Council of New Zealand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Auckland Health Research Ethical Committee of The University of Auckland, The University of Calgary and The Human Research Ethics Committee of Western Sydney University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used for analysis will be made available upon reasonable request, conditional on ethical approvals.